title: Systematic Chemical Mutagenesis Identifies a Potent Novel Apratoxin A/E Hybrid with Improved in Vivo Antitumor Activity.
abstract: Apratoxins are cytotoxic marine natural products that prevent cotranslational translocation early in the secretory pathway. We showed that apratoxins downregulate receptors and growth factor ligands, giving a one-two punch to cancer cells, particularly those that rely on autocrine loops. Through total synthesis, we tested the effects of amino acid substitutions, including alanine scanning, on the downregulation of receptor tyrosine kinases and vascular endothelial growth factor A (VEGF-A) and probed the stereospecificity of target engagement by epimerization of selected chiral centers. Differential effects on two types of secretory molecules suggest that the apratoxins' substrate selectivity with respect to inhibition of secretion may be tuned through structural modifications to provide tailored therapy. Our structure-activity relationship studies and medicinal chemistry efforts led to a potent inhibitor with in vivo efficacy in a colorectal tumor xenograft model without irreversible toxicity exerted by apratoxin A, demonstrating that this novel mechanism of action has therapeutic potential.
authors.affiliation: Department of Medicinal Chemistry,  University of Florida , Gainesville, Florida 32610, United States.
authors.forename: Qi-Yin
authors.initials: QY
authors.lastname: Chen
authors.forename: Yanxia
authors.initials: Y
authors.lastname: Liu
authors.forename: Hendrik
authors.initials: H
authors.lastname: Luesch
references.citation: Curr Med Chem. 2011;18(11):1599-612
references.pmid: 21428886
references.citation: Clin Cancer Res. 2010 Oct 15;16(20):4990-5001
references.pmid: 20810384
references.citation: N Engl J Med. 2004 Jun 3;350(23):2335-42
references.pmid: 15175435
references.citation: J Cell Biol. 2009 May 18;185(4):629-39
references.pmid: 19433452
references.citation: Mol Pharmacol. 2009 Jul;76(1):91-104
references.pmid: 19403701
references.citation: Science. 2006 May 26;312(5777):1175-8
references.pmid: 16728632
references.citation: Chem Asian J. 2009 Jan 5;4(1):111-25
references.pmid: 19034894
references.citation: J Am Chem Soc. 2001 Jun 13;123(23):5418-23
references.pmid: 11389621
references.citation: Oncology. 2009;77(6):400-10
references.pmid: 20130423
references.citation: Chem Asian J. 2011 Jan 3;6(1):180-8
references.pmid: 21080404
references.citation: Med Oncol. 2004;21(1):1-8
references.pmid: 15034208
references.citation: Nature. 2000 Sep 14;407(6801):249-57
references.pmid: 11001068
references.citation: J Nat Prod. 2008 Jun;71(6):1099-103
references.pmid: 18444683
references.citation: Bioorg Med Chem. 2002 Jun;10(6):1973-8
references.pmid: 11937357
references.citation: Nat Med. 1995 Jan;1(1):27-31
references.pmid: 7584949
references.citation: Chembiochem. 2010 Jul 5;11(10):1458-66
references.pmid: 20512792
references.citation: Nat Biotechnol. 2006 Aug;24(8):871-2
references.pmid: 16900109
references.citation: J Am Chem Soc. 2002 Apr 17;124(15):3824-5
references.pmid: 11942807
references.citation: J Am Chem Soc. 2003 Jul 23;125(29):8734-5
references.pmid: 12862462
references.citation: J Nat Prod. 2008 Jun;71(6):1113-6
references.pmid: 18461997
references.citation: Chemistry. 2006 Oct 10;12(29):7615-26
references.pmid: 16832801
references.citation: J Clin Oncol. 2007 Mar 1;25(7):884-96
references.pmid: 17327610
references.citation: Org Lett. 2006 Feb 2;8(3):531-4
references.pmid: 16435877
references.citation: Nat Chem Biol. 2006 Mar;2(3):158-67
references.pmid: 16474387
references.citation: Carcinogenesis. 2000 Mar;21(3):505-15
references.pmid: 10688871
references.citation: Angew Chem Int Ed Engl. 2003 Jan 3;42(1):83-5
references.pmid: 19757597